Company Overview
| Stock Name | Microport Neuro |
|---|---|
| Stock Code | 02172 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 神經介入醫療器械行業的中國公司,致力於向醫生及患者提供創新解決方案,產品涵蓋出血性腦卒中、腦動脈粥樣硬化狹窄及急性缺血性腦卒中三大領域。 |
| Listing Date | 2022-07-15 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 上海市浦東新區芙蓉花路500號19號樓 |
| Business Address (Hong Kong) | 香港九龍觀塘道348號宏利廣場5樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | medneurotech.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 24.64 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 1,000 shares |
| Entry Threshold | HK$ 24,640 |
| Par Value | To be extracted |
| Offer Period | 2022-06-29 to 2022-07-08 |
| Global Offering Shares | 13,700,000 shares |
| HK Public Offer Shares (Initial) | 1,370,000 shares (10.0%) |
| Public Offer Lots (Initial) | 1,370lots (Pool A685lots,Pool B685lots) |
| International Placing Shares (Initial) | 12,330,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 582,658,100 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 65.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 337,568,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 1,000 | HK$ 24,640 |
| 2 lots | 2,000 | HK$ 49,280 |
| 3 lots | 3,000 | HK$ 73,920 |
| 4 lots | 4,000 | HK$ 98,560 |
| 5 lots | 5,000 | HK$ 123,200 |
| 6 lots | 6,000 | HK$ 147,840 |
| 7 lots | 7,000 | HK$ 172,480 |
| 8 lots | 8,000 | HK$ 197,120 |
| 9 lots | 9,000 | HK$ 221,760 |
| 10 lots | 10,000 | HK$ 246,400 |
| 12 lots | 12,000 | HK$ 295,680 |
| 14 lots | 14,000 | HK$ 344,960 |
| 16 lots | 16,000 | HK$ 394,240 |
| 18 lots | 18,000 | HK$ 443,520 |
| 20 lots | 20,000 | HK$ 492,800 |
| 25 lots | 25,000 | HK$ 616,000 |
| 30 lots | 30,000 | HK$ 739,200 |
| 35 lots | 35,000 | HK$ 862,400 |
| 40 lots | 40,000 | HK$ 985,600 |
| 45 lots | 45,000 | HK$ 1,108,800 |
| 50 lots | 50,000 | HK$ 1,232,000 |
| 60 lots | 60,000 | HK$ 1,478,400 |
| 70 lots | 70,000 | HK$ 1,724,800 |
| 80 lots | 80,000 | HK$ 1,971,200 |
| 90 lots | 90,000 | HK$ 2,217,600 |
| 100 lots | 100,000 | HK$ 2,464,000 |
| 100 lots | 100,000 | HK$ 2,464,000 |
| 120 lots | 120,000 | HK$ 2,956,800 |
| 140 lots | 140,000 | HK$ 3,449,600 |
| 160 lots | 160,000 | HK$ 3,942,400 |
| 180 lots | 180,000 | HK$ 4,435,200 |
| 200 lots | 200,000 | HK$ 4,928,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 250 lots | 250,000 | HK$ 6,160,000 |
| 300 lots | 300,000 | HK$ 7,392,000 |
| 350 lots | 350,000 | HK$ 8,624,000 |
| 400 lots | 400,000 | HK$ 9,856,000 |
| 450 lots | 450,000 | HK$ 11,088,000 |
| 500 lots | 500,000 | HK$ 12,320,000 |
| 685 lots | 685,000 | HK$ 16,878,400 |
Stock Connect Inclusion Analysis
| Avg Daily HK Mkt Cap | HK$ 5.45B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 14,356,695,584 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利约人民币24.2百万元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 59,468,000 |
| Listing Expenses / Funds Raised | ~17.62% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Operating profit | 52,411 | 51,397 | 31,903 |
| Share of associates and JVs | 7,517 | ||
| Profit before tax | 52,411 | 51,397 | 31,903 |
| Income tax expense | 5,436 | 6,109 | 7,733 |
| Profit for the year | 46,975 | 45,286 | 24,170 |
Income Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 24.6 |
|---|---|
| First Day Open | HK$ 24.7 |
| First Day Change | -0.16% |
| First Day Volume | 3266920.0 |
| First Day Turnover | 80710300.0 |
| Use of Proceeds | 1、約93.4百萬港元(占估計所得款項凈額的30.0%)將用于研發出血性腦卒中、腦動脈粥樣硬化狹窄及急性缺血性腦卒中治療及通路產品;
2、約55.6百萬港元(占估計所得款項凈額的20.0%)將用于出血性腦卒中、腦動脈粥樣硬化狹窄及急性缺血性腦卒中產品商業化;
3、約41.7百萬港元(占估計所得款項凈額的15.0%)將用于擴張制造設施以擴大生產規模;
4、約55.6百萬港元(占所得款項凈額的20.0%)將用于擴大全球影響力;
5、約27.8百萬港元(占估計所得款項凈額的10.0%)將用于通過戰略收購、投資、合作或該等策略的結合以優化產品組合;
6、約13.9百萬港元(占所得款項凈額的5.0%)將用作營運資金及其他一般公司用途。 |
Underwriting Syndicate
Overall Coordinators (2)
Joint Bookrunners (4)
Joint Lead Managers (4)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Harvest International Premium Value (Secondary Market) Fund SPC | 146,287,680 HKD | — | 43.30% | — | 6 months | 2023-01-15 |
| 2 | 新华网股份有限公司 | 73,131,520 HKD | — | 21.70% | — | 6 months | 2023-01-15 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 彭博 | — |
| Company Secretary | 許燕珊 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 緊隨全球發售完成後(假設超額配股權未獲行使),MP Scientific(由微創醫療全資擁有)持股53.35%,中國微創投資管理持股10.39%,Maxwell Maxcare Science Foundation Limited持股10.97%。 |
|---|




